Ritlecitinib: Efficacy Of A Novel Therapy For Severe Alopecia Areata In Patients Aged 12 Years And Older

December 2025 in “ Actas Dermo-Sifiliográficas ”

Sergio Vañó‐Galván, I. Figueras-Nart, Carlos Serrano, Maria Pilar Fortes, Valeria Herrera-Lasso, R Botella-Estrada

ritlecitinib JAK3/TEC kinase inhibitor alopecia areata Janus kinases JAK pathway immunosuppressive treatments

TLDR Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Ritlecitinib, a JAK3/TEC kinase inhibitor, has been approved for treating severe alopecia areata (AA) in patients aged 12 and older. This novel therapy targets the Janus kinases (JAK) pathway, which plays a crucial role in the disease's pathogenesis, offering a new approach compared to traditional nonspecific immunosuppressive treatments. The review discusses ritlecitinib's mechanism of action and provides evidence supporting its safety and efficacy in managing severe AA.

View this study on sciencedirect.com →

Discuss this study in the Community →

Research cited in this study

14 / 14 results

research Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme

13 citations , February 2025 in “Journal of the European Academy of Dermatology and Venereology”

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

research Systematic Review and Indirect Treatment Comparisons of Ritlecitinib Against Baricitinib in Alopecia Areata

October 2024 in “Journal of the European Academy of Dermatology and Venereology”

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

Impact of Previous Alopecia Areata Treatment on Efficacy Responses Up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis

research Impact of Previous Alopecia Areata Treatment on Efficacy Responses Up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis

3 citations , September 2024 in “Dermatology and Therapy”

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata

4 citations , January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

research Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database

1 citations , June 2023 in “Dermatology and therapy”

People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.